No publicly traded investment with a specific ticker or price target was identified; the strongest opportunities discussed are private businesses, so there is no clear actionable stock trade. The guest claims AlgorX has about $20 million in annual sales, up roughly sixfold in a year, but verify revenue, profitability, valuation, and reliance on his promotion before considering any investment. HTLT’s entry into GNC could support growth, but the discussion provides no sales or profit data to confirm the opportunity. Treat both businesses as high-uncertainty prospects, and monitor GLP-1 drug approvals and safety evidence rather than investing based on unapproved treatments or unverified claims.

GLP-1 and Obesity-Drug Market

• The guest said weight-loss drugs such as Ozempic, tirzepatide, and experimental retatrutide could make obesity less common over the next decade.
• He described retatrutide as potentially more effective for weight loss but also riskier, citing increased resting heart rate and nausea. He said it was not yet approved and advised against using it outside appropriate medical oversight.
• He also raised concerns about side effects associated with GLP-1 drugs, including reduced enjoyment or motivation and a possible risk of optic-nerve damage with Ozempic. These were the guest’s claims, not independently established findings in the discussion.
• No drug manufacturers, stock tickers, price targets, or investment recommendations were named.

Takeaways

• The discussion points to potential growth in the obesity-treatment market, but it does not identify a specific security to invest in.
• Drug approval status, safety evidence, and side effects are important factors to monitor; the guest specifically characterized retatrutide as unapproved and higher-risk.

AlgorX

• The guest said he owns part of AlgorX, a company selling peptides, and estimated that it generates about $20 million in annual sales.
• He said sales had increased roughly sixfold since he became involved about a year earlier, and that he advertises the company in his videos.
• The transcript does not provide profitability, valuation, ownership details, or independently verified financial figures.

Takeaways

• AlgorX is the clearest direct private-business opportunity discussed, with the guest describing substantial sales growth.
• Treat the figures as the owner’s claims: the discussion offers no information on margins, valuation, or how much growth depends on the guest’s audience and promotion.

HTLT Supplements and GNC

• The guest said his supplement brand, referred to in the transcript as HGLT (likely HTLT), had entered GNC.
• He described the retail placement as a major step and said it could help the brand expand to other retailers and international markets.
• He also said the company was developing products that he believes distinguish it from competitors. No sales figures, valuation, or stock ticker were provided.

Takeaways

• Retail distribution could provide a growth channel for the supplement business, but the transcript does not establish whether the GNC launch has translated into meaningful revenue or profit.
• The guest is an owner and promoter of the business, so his favorable outlook is interested commentary rather than independent analysis.

Bodybuilding and Fitness-Creator Economics

• The guest said top-level open bodybuilding preparation can cost upwards of $100,000 per year, while major competitions may award roughly $500,000–$600,000 to the winner.
• He described coaching and product sales as common ways bodybuilders earn income, and said some competitors sell steroids to help cover their own costs.

Takeaways

• The discussion portrays elite bodybuilding as a high-cost, uncertain business rather than a straightforward prize-money opportunity.
• The guest’s comments suggest that coaching, products, and audience-driven businesses may be important income sources in the fitness industry, but no specific investment or company recommendation was made.